Candida auris in India: The Drug-Resistant Fungal Superbug

A family member goes into the ICU for a routine post-surgical recovery, everything looks stable — and then, days later, doctors mention a fungal infection that "doesn't respond to the usual medicines." For a growing number of Indian ICU patients, that infection is Candida auris, a drug-resistant yeast that global health authorities now rank among the most dangerous emerging superbugs on earth. India was one of the first countries in the world to identify it — and it hasn't gone away since.

Unlike the fungal skin infections most Indians are familiar with, C. auris doesn't cause itching or rashes. It invades the bloodstream, spreads silently through hospital wards, and resists many of the antifungal drugs doctors depend on. Here's what every family with a hospitalised or critically ill relative should understand about it.

What Is Candida auris?

Candida auris is a species of yeast — a type of fungus — first identified in 2009 from the ear canal of a patient in Japan (hence "auris," Latin for ear). Since then, it has emerged independently on multiple continents as a serious healthcare-associated pathogen, now reported in over 40 countries, including India, where some of the earliest and most significant case series in the world were documented.

What makes C. auris different from the common Candida albicans that causes oral thrush or vaginal yeast infections is threefold:

• Multidrug resistance: Many strains resist one or more — sometimes all — of the major classes of antifungal drugs
• Environmental persistence: It survives for weeks on hospital surfaces, bedrails, and equipment, resisting many standard disinfectants
• Misidentification risk: Older laboratory identification methods frequently mistake it for other, less dangerous Candida species, delaying correct treatment

Indian researchers — including microbiologist Dr Anuradha Chowdhary, whose early work helped put India's C. auris burden on the global map — identified cases in ICU patients across north, south, east, and central India well over a decade ago. Since then, hospitals from Delhi and Chandigarh to Chennai and Kolkata have documented outbreaks, particularly in intensive care settings.

Why It Matters: Not a Skin Infection

It's important to distinguish C. auris from the fungal skin infections (ringworm, athlete's foot) that are extremely common in India's hot, humid climate. C. auris is almost exclusively a healthcare-associated, invasive infection — meaning it enters the bloodstream, urinary tract, or surgical wounds of patients who are already critically ill, not a superficial skin condition affecting otherwise healthy people.

Who is at risk:

• Patients in ICUs, especially those on ventilators for extended periods
• Patients with central venous catheters or urinary catheters
• People who have received broad-spectrum antibiotics or antifungal drugs for prolonged periods
• Post-surgical patients, especially after abdominal or cardiac surgery
• Patients with diabetes, kidney disease, or weakened immunity
• Neonates in intensive care, and patients who have had long hospital stays or multiple hospital transfers

Healthy people going about daily life are essentially not at risk of invasive C. auris infection. This is a hospital-corridor problem, not a household one — but for families with a relative in critical care, it's one worth understanding.

Why C. auris Is So Hard to Treat

There are only four major classes of antifungal drugs available worldwide (compared to dozens of antibiotic classes for bacteria), and C. auris has already shown resistance to multiple classes in a significant proportion of Indian isolates:

Because of this, echinocandins are generally the first-line treatment for confirmed C. auris bloodstream infections in India, but doctors sometimes need to combine drugs or switch to amphotericin B-based regimens when echinocandins fail or aren't tolerated. In the most resistant cases — sometimes called pan-resistant strains, where no drug class works reliably — treatment options narrow dramatically, and mortality in critically ill patients with persistent candidaemia has been reported as high as 50% in some published Indian and international case series, though this reflects both the infection and the severity of the underlying illness.

How It Spreads in Hospitals

C. auris doesn't spread through the air like a respiratory virus. It spreads through:

• Direct contact with contaminated hands of healthcare workers
• Contaminated equipment: thermometers, blood pressure cuffs, ventilator tubing, catheters
• Environmental surfaces: bedrails, curtains, furniture — it can survive on dry surfaces for weeks
• Colonised patients: some people carry C. auris on their skin without symptoms, unknowingly spreading it to surfaces and other patients

This is why outbreaks tend to cluster within specific ICUs or hospital wards rather than spreading community-wide, and why hospital infection control practices are the single biggest factor in containing it.

Diagnosis: Why Identification Matters

Traditional biochemical identification methods used in many Indian labs can misidentify C. auris as other, more treatable Candida species — a dangerous gap, since the wrong species assumption can lead to the wrong (ineffective) antifungal being prescribed.

Accurate identification requires:

• MALDI-TOF mass spectrometry: Available at major tertiary care centres and reference labs (AIIMS, PGIMER, and select private labs) — fast and highly accurate
• Molecular methods (PCR-based sequencing): The most definitive identification method, used to confirm species and, increasingly, to detect resistance markers
• ICMR's National Reference Laboratories: Provide confirmatory testing support for hospitals that suspect C. auris but lack in-house advanced diagnostics

If a family member develops a bloodstream infection (candidaemia) during a hospital stay that isn't responding to standard antifungal treatment, it's reasonable to ask the treating team whether C. auris has been considered and whether advanced species identification is available or needed.

Symptoms: What Families Should Watch For

Because C. auris almost always occurs in patients who are already critically ill, its symptoms often overlap with — and are masked by — the underlying illness. There is no distinctive "C. auris symptom." Signs that suggest a bloodstream fungal infection in a hospitalised patient include:

• Fever that doesn't respond to antibiotics, especially in a patient already on broad-spectrum antibiotics
• New or worsening low blood pressure in an ICU patient
• Signs of sepsis: rapid heart rate, confusion, reduced urine output
• Persistent positive blood cultures despite treatment

If your family member has been in an ICU for an extended period and develops a new, unexplained fever, it's reasonable to ask whether fungal cultures — not just bacterial ones — have been sent.

Treatment Approach in Indian Hospitals

• Echinocandins (caspofungin, micafungin, anidulafungin) are typically first-line for confirmed candidaemia due to C. auris, given intravenously in a hospital setting
• Removal of infected catheters or lines wherever possible — a colonised catheter can act as a persistent source of infection even with antifungal treatment
• Combination therapy or amphotericin B for cases showing resistance to echinocandins, guided by antifungal susceptibility testing where available
• Source control: draining abscesses, addressing any surgical site involvement
• Strict infection control measures: contact precautions, dedicated equipment, enhanced environmental cleaning with disinfectants proven effective against C. auris (standard alcohol-based hand sanitisers are less effective against it than against bacteria, so hospitals use specific decontamination protocols)

Treatment duration and choice of drug should always be guided by an infectious disease specialist and susceptibility testing where available, since resistance patterns vary between hospitals and regions.

What This Means for India's Broader AMR Crisis

C. auris is often discussed alongside bacterial superbugs as part of India's wider antimicrobial resistance crisis — and the same root causes apply: overuse of broad-spectrum antimicrobials, prolonged ICU stays, invasive devices, and gaps in hospital infection control all create the conditions where resistant organisms thrive.

The World Health Organization has placed C. auris on its fungal priority pathogens list in the "critical" category — the highest tier of concern — reflecting both its resistance profile and its potential to spread within healthcare settings globally. India's ICMR continues to expand surveillance of C. auris through its network of tertiary care hospitals, though experts note that under-reporting remains a challenge, particularly outside major metros.

What Families Can Do

For most Indian families, this is not a threat to plan around in daily life — but if you have a relative who is critically ill, undergoing major surgery, or facing a prolonged ICU stay, a few things help:

• Ask about infection control practices at the hospital — dedicated equipment, hand hygiene compliance, and isolation protocols for known C. auris patients are reassuring signs of a well-run ICU
• Don't request antibiotics or antifungals for family members unless a doctor has specifically diagnosed an infection requiring them — inappropriate use accelerates resistance
• Ask questions if fever persists despite treatment — advocate for appropriate cultures to be sent, including fungal cultures where relevant
• Keep records of every antibiotic and antifungal course your family member receives during a hospital stay — this history matters enormously if they're readmitted or transferred to another facility later

Uploading discharge summaries, culture reports, and medication records to MedicalVault after a hospital stay means this information travels with your family member to their next doctor — critical when managing complex, resistant infections across multiple hospital visits. The family sharing feature is particularly useful for adult children coordinating a parent's care across specialists.

Key Takeaways

• Candida auris is a drug-resistant fungal superbug, first identified in 2009, with India among the earliest countries to report significant cases — it is a hospital-acquired bloodstream infection, not a skin condition
• It mainly threatens critically ill, hospitalised patients — those in ICUs, on ventilators, with catheters, or on prolonged antibiotic/antifungal therapy — not the general public
• It resists multiple antifungal drug classes, especially fluconazole, making correct laboratory identification (MALDI-TOF or molecular testing) essential for effective treatment
• Echinocandins are the usual first-line treatment, though resistance is rising and some strains require combination therapy
• It spreads through contaminated hospital surfaces and equipment, not through the air or casual contact — hospital infection control is the primary defence
• The WHO ranks it a "critical" priority fungal pathogen, underscoring the global and Indian urgency around antifungal stewardship
• Families with critically ill relatives should ask about infection control practices and keep thorough records of every antimicrobial course given — MedicalVault helps consolidate this history across a hospital stay and beyond